| Literature DB >> 33240024 |
Suzan Demir Pektas1, Nese Cinar2, Deniz Demircioglu Duman3, Ahmet Kara4, Janserey Batu5, Sevim Karakas-Celik6, Duygu Yazgan Aksoy7.
Abstract
INTRODUCTION: Ghrelin has anti-inflammatory and immunomodulatory activities. Data about the role of ghrelin and ghrelin polymorphisms in the development of acne vulgaris in post-adolescent male patients are limited. AIM: To evaluate the role of serum androgens, insulin resistance, ghrelin and ghrelin polymorphisms in severe acne vulgaris.Entities:
Keywords: acne vulgaris; ghrelin; ghrelin polymorphisms; insulin resistance; post-adolescent
Year: 2020 PMID: 33240024 PMCID: PMC7675091 DOI: 10.5114/ada.2020.100492
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
PCR-RFLP conditions of the polymorphisms of the ghrelin genes
| Gene | Polymorphism | Primers | Temperature of annealing [°C] | Restriction endonuclease | PCR products |
|---|---|---|---|---|---|
| Ghrelin | rs27647 | P1 | 65 | G allele: 664 and 265 bp | |
| rs34911341 | P3 | 53 | G allele: 455 and 163 bp | ||
| rs696217 | P3 | 65 | Bsr-I | C allele: 517 and 101 bp |
P1 – 5′-CACAGCAACAAAGCTGCACC-3′, P2 – 5′-AAGTCCAGCCAGAGCATGCC-3′, P3 – 5′-GCTGGGCTCCTACCTGAGC-3′, P4 – 5′-GGACCCTGTTCACTGCCAC-3′.
Comparison of the clinical characteristics and biochemical parameters of the control and post-adolescent male patients with acne vulgaris
| Parameter | Control group | Acne vulgaris group | |
|---|---|---|---|
| Age [years] | 28.4 ±4.9 | 28.0 ±5.4 | NS |
| Weight [kg] | 72.8 ±6.8 | 73.7 ±7.5 | NS |
| BMI [kg/m2] | 23.9 ±2.1 | 23.7 ±2.2 | NS |
| WHR | 0.86 ±0.08 | 0.92 ±0.06 | < 0.05 |
| Systolic BP [mm Hg] | 117.1 ±6.8 | 112.8 ±10.4 | NS |
| Diastolic BP [mm Hg] | 73.7 ±6.9 | 75.5 ±6.6 | NS |
| FPG [mg/dl] | 87.8 ±11.5 | 88.1 ±7.1 | NS |
| Basal insulin [mU/l] | 10.1 ±5.6 | 11.8 ±6.8 | NS |
| HOMA-IR | 2.2 ±1.3 | 2.5 ±1.5 | NS |
| LDL-C [mg/dl] | 108.3 ±34.7 | 87.6 ±28.4 | < 0.05 |
| Triglyceride [mg/dl] | 128 ±66.3 | 111.8 ±50.4 | NS |
| TC [mg/dl] | 184.6 ±40.3 | 160 ±33.7 | < 0.05 |
| HDL-C [mg/dl] | 54.1 ±14.4 | 55.8 ±17.3 | NS |
| FSH [mIU/ml] | 5.7 ±1.4 | 3.7 ±1.7 | < 0.001 |
| LH [mIU/ml] | 5.5 ±1.4 | 5.1 ±1.8 | NS |
| Total testosterone [ng/ml] | 4.9 ±1.6 | 5.3 ±1.9 | NS |
| SHBG [nmol/l] | 29 ±9.7 | 30.7 ±16.4 | NS |
| FAI | 19.2 ±10.6 | 20.8 ±15.6 | NS |
| DHEAS [µg/dl] | 297.5 ±46.3 | 336.7 ±125.7 | NS |
| Ghrelin [pg/ml] | 101.2 ±86.5 | 4.5 ±5.8 | < 0.001 |
Data were presented as mean ± SD, The p-values < 0.05 were assessed as statistically significant. N – number of volunteers, NS – non-significant, BMI – body mass index, WHR – waist to hip ratio, BP – blood pressure, FPG – fasting plasma glucose, HOMA-IR – homeostatic model assessment of insulin resistance, LDL-C – low-density lipoprotein cholesterol, TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LH – luteinizing hormone, FSH – follicle stimulating hormone, SHBG – sex hormone binding globulin, FAI – free androgen index, DHEAS – dehydroepiandrosterone sulphate.
Genotype and allele frequencies of ghrelin gene variants in post-adolescent male patients with acne vulgaris and healthy controls
| Ghrelin gene | Controls | Acne vulgaris | OR (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| rs27647: | |||||||
| AA | 17 (51.5) | 4 (11.4) | Reference | 0.002 | |||
| GA | 8 (24.2) | 21 (60) | 11.156 (2.864–43.464) | 0.001 | |||
| GG | 8 (24.2) | 10 (28.6) | 5.312 (1.269–22.244) | 0.022 | |||
| rs34911341: | |||||||
| GG | 33 (100) | 35 (100) | |||||
| rs696217: | |||||||
| CC | 23 (69.6) | 24 (68.6) | Reference | 0.817 | |||
| AA | 5 (15.2) | 4 (14.4) | 0.767 (0.183–3.216) | 0.716 | |||
| CA | 5 (15.2) | 7 (20.0) | 1.342 (0.372–4.836) | 0.653 | |||
The p-values < 0.05 were considered as statistically significant.
Comparison of the clinical characteristics and biochemical parameters of the alleles of ghrelin rs27647 gene genotype in the post-adolescent patients with acne vulgaris
| Parameter | AA ( | GA ( | GG ( | |
|---|---|---|---|---|
| Age [years] | 25.0 ±3.2 | 27.9 ±5.6 | 29.4 ±5.8 | NS |
| Disease duration [years] | 6.7 ±3.5 | 5.4 ±1.7ª | 8.5 ±3.1 | < 0.007 |
| GAGS | 6.7 ±14.1b,c | 24.6 ±15.7 | 19.4 ±17.9 | 0.001 |
| Weight [kg] | 70 ±7.1 | 74.6 ±6.9 | 73.3 ±9.1 | NS |
| BMI [kg/m2] | 22.4 ±2.9 | 23.9 ±2.1 | 23.8 ±2.6 | NS |
| WHR | 0.8 ±0.0 | 0.9 ±0.0 | 0.9 ±0.0 | NS |
| Systolic BP [mm Hg] | 110 ±8.1 | 111.4 ±11.5 | 117 ±8.2 | NS |
| Diastolic BP [mm Hg] | 71.2 ±2.5 | 75.2 ±7.4 | 78 ±4.8 | NS |
| FPG [mg/dl] | 87.2 ±9 | 89 ±6.5 | 86.6 ±8 | NS |
| Basal insulin [mU/l] | 12.7 ±12.5 | 12.1 ±6.5 | 10.7 ±5.3 | NS |
| HOMA-IR | 2.9 ±3.1 | 2.6 ±1.4 | 2.3 ±1.1 | NS |
| LDL-C [mg/dl] | 21.7 ±10.8 | 29 ±6.3 | 30.6 ±9.7 | NS |
| Triglyceride [mg/dl] | 75 ±32 | 124 ±56.4 | 101 ±33.6 | NS |
| TC [mg/dl] | 184.2 ±40.2 | 157.2 ±29.9 | 156 ±38.5 | NS |
| HDL-C [mg/dl] | 68.7 ±27.6 | 53 ±14.8 | 56.6 ±17.2 | NS |
| FSH [mIU/ml] | 2.8 ±1.8 | 3.4 ±1.4 | 4.5 ±2 | NS |
| LH [mIU/ml] | 6.4 ±0.5 | 4.9 ±1.8 | 4.8 ±2 | NS |
| Total testosterone [ng/ml] | 7.1 ±2.3 | 4.8 ±1.7 | 5.6 ±1.7 | NS |
| SHBG [nmol/l] | 47 ±36.5 | 29.9 ±11.8 | 25.8 ±11.1 | NS |
| FAI | 18.6 ±6 | 16.9 ±4.9 | 29.8 ±26.9 | NS |
| DHEAS [µg/dl] | 479.2 ±197 | 312.9 ±110.8 | 329.9 ±95.2 | NS |
| Ghrelin [pg/ml] | 2.9 ±0.6 | 4.6 ±5.5 | 4.8 ±7.6 | NS |
Data were presented as mean ± SD, The p-values < 0.05 were assessed as statistically significant. N – number of volunteers, NS – non-significant, GAGS – global acne grading score, BMI – body mass index, WHR – waist to hip ratio, BP – blood pressure, FPG – fasting plasma glucose, HOMA-IR – homeostatic model assessment of insulin resistance, LDL-C – low-density lipoprotein cholesterol, TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LH – luteinizing hormone, FSH – follicle stimulating hormone, SHBG – sex hormone binding globulin, FAI – free androgen index, DHEAS – dehydroepiandrosterone sulphate. ªp < 0.05; GA allele group vs. GG allele group. bp < 0.05; AA allele group vs. GG allele group. cp < 0.05; AA allele group vs. GA allele group.
Comparison of the clinical characteristics and biochemical parameters of the alleles of ghrelin rs696217 gene genotype in the post-adolescent male patients with acne vulgaris
| Parameter | CC ( | AA ( | CA ( | |
|---|---|---|---|---|
| Age [years] | 28.0 ±4.9 | 23.2 ±2.6 | 30.8 ±6.9 | NS |
| Disease duration [years] | 6.5 ±2.8 | 5.5 ±2.5 | 6.8 ±3.1 | NS |
| GAGS | 17.5 ± 17.5 | 15.4 ±18.4 | 20.0 ±17.8 | NS |
| Weight [kg] | 73.6 ±8.1 | 72 ±4.5 | 75 ±7.3 | NS |
| BMI [kg/m2] | 24 ±2.3 | 23.1 ±0.8 | 23 ±2.5 | NS |
| WHR | 0.9 ±0.0 | 0.9 ±0.1 | 0.9 ±0.0 | NS |
| Systolic BP [mm Hg] | 112 ±11.7 | 115 ±5.7 | 111.2 ±7.8 | NS |
| Diastolic BP [mm Hg] | 75 ±6.9 | 76.2 ±7.5 | 77.1 ±5.6 | NS |
| FPG [mg/dl] | 88.4 ±6.8 | 87.5 ±7.8 | 87.5 ±8.8 | NS |
| Basal insulin [mU/l] | 11.3 ±5.7 | 6.8 ±2.9 | 16.2 ±9.7 | NS |
| HOMA-IR | 2.5 ±1.3 | 1.5 ±0.6 | 3.5 ±2.1 | NS |
| LDL-C [mg/dl] | 81 ±29.6 | 114.2 ±9.9 | 94.9 ±21.5 | NS |
| Triglyceride [mg/dl] | 122.6 ±53.6 | 85.5 ±45.7 | 90.1 ±29.4 | NS |
| TC [mg/dl] | 152 ±32.6 | 181.7 ±31 | 174.8. ±32.8 | NS |
| HDL-C [mg/dl] | 53.7 ±14.9 | 59.2 ±20.8 | 61.2 ±23.7 | NS |
| FSH [mIU/ml] | 3.4 ±1.5 | 4.3 ±2.8 | 4 ±1.7 | NS |
| LH [mIU/ml] | 4.9 ±1.9 | 6.6 ±0.3 | 4.5 ±1.7 | NS |
| Total testosterone [ng/ml] | 5.1 ±1.6 | 6.4 ±2.9 | 5.3 ±2.3 | NS |
| SHBG [nmol/l] | 28.3 ±11.2 | 44 ±38.3 | 31.2 ±13.3 | NS |
| FAI | 21.4 ±17.3 | 18.1 ±6.7 | 20.1 ±14 | NS |
| DHEAS [µg/dl] | 338.1 ±86.3ª | 522.2 ±165.2 | 226.3 ±101.1b | < 0.05 |
| Ghrelin [pg/ml] | 4.8 ±6.7 | 2.5 ±1.9 | 4.4 ±3.4 | NS |
Data were presented as mean ± SD, The p-values < 0.05 were assessed as statistically significant. N – number of volunteers, NS – non-significant, GAGS – global acne grading score, BMI – body mass index, WHR – waist to hip ratio, BP – blood pressure, FPG – fasting plasma glucose, HOMA-IR – homeostatic model assessment of insulin resistance, LDL-C – low-density lipoprotein cholesterol, TC – total cholesterol, HDL-C – high-density lipoprotein cholesterol, LH – luteinizing hormone, FSH – follicle stimulating hormone, SHBG – sex hormone binding globulin, FAI – free androgen index, DHEAS – dehydroepiandrosterone sulphate. ªp < 0.05; CC allele group vs. AA allele group. bp < 0.05; CC allele group vs. CA allele group.